[{"id":"178c0736-cfc2-4e01-952f-bd1c2245a857","acronym":"","url":"https://clinicaltrials.gov/study/NCT03048344","created_at":"2021-01-18T15:00:43.403Z","updated_at":"2024-07-02T16:37:01.361Z","phase":"Phase 1","brief_title":"A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders","source_id_and_acronym":"NCT03048344","lead_sponsor":"Orsenix LLC","biomarkers":" NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arsenic trioxide • arsenic trioxide oral (SY-2101)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/02/2016","start_date":" 12/02/2016","primary_txt":" Primary completion: 02/28/2019","primary_completion_date":" 02/28/2019","study_txt":" Completion: 02/28/2019","study_completion_date":" 02/28/2019","last_update_posted":"2019-03-25"}]